Anticancer drugs strive for zero tax rate, Nawu monoclonal antibody and other five imported anticancer drugs will be listed soon

Medical Network March 26th On the morning of March 20th, after the closing of the 13th National People's Congress, the Premier of the State Council said in response to questions from Chinese and foreign journalists that he is willing to further reduce the overall tax rate of imported goods in a more open manner. "Some of the hot-selling consumer goods in the market include medicines, especially the anti-cancer drugs that the masses and patients urgently need. We have to reduce them to a zero rate." The Prime Minister is simply a single sentence with a huge amount of information. Many cancer patients have brought a new dawn.

Current status of drug use in cancer patients in China

For a long time, some cancer patients in China must rely on imported targeted drugs and some innovative drugs to continue their lives. However, due to patent restrictions, these drugs are often extremely expensive, and the price of a single anticancer drug is tens of thousands of dollars, and cannot be reimbursed through medical insurance. Faced with the burden of “buying life with money”, many people choose to give up, and some people are forced to join the “drug- buying army” to purchase low-cost “generic drugs” in neighboring countries such as India. The increase in the phenomenon of "haitao" drugs, although it can temporarily relieve the pain and stabilize the disease, but because there is no doctor's guidance, the adverse reactions of drugs are not monitored, and the safety is not guaranteed. The “Lu Yong” case, which was raging in 2014, also reflected the inability of some cancer patients in China to afford high-priced imported drugs. Anti-cancer drugs strive to reduce to zero tariffs, will immediately reduce the price of drugs, reduce the economic burden of patients and their families, while foreign pharmaceutical companies have more price space to compete in China's anti-cancer market.

68 imported anti-cancer drugs, 31 exclusive varieties

According to the CFDA imported drug database data, there are currently 68 imported anti-cancer drugs, of which 31 are exclusive varieties and only 4 are biological agents (both monoclonal antibodies). Among them, the number of fentanic drugs is the highest, totaling 16 models. According to the data from the MED China Drug Evaluation Database 2.0, there are currently more than 20 domestic companies that have arranged for the fennitril. The fennitril will usher in a blowout in the next few years, and the competition will become fiercer. Traditional chemotherapeutic drugs such as antimetabolites, hormones, and alkylating agents still occupy a large proportion, and there are only four relatively high-end bio-targeting agents, and the proportion of anti-cancer drugs in developed countries is quite different. However, with the increasing emphasis on drug research and development in China, and the continuous implementation of various incentive policies, it is believed that more and better drugs will continue to be listed in the near future.

Statistics on the types of 68 imported anticancer drugs (by product name)

Source: Mene net comprehensive finishing

Imported anti-cancer brand TOP10 , Roche's one big

2013-2016 public medical institution market imported anti-cancer drug brand TOP10

Source: Minernet China's public medical institutions terminal competition pattern

Roche has ranked first in the market for anticancer drug companies for many years, and is the only company with a share of more than 10%. It has rituximab injection, capecitabine tablets, trastuzumab injection, and bevacate. The four key anti-cancer products of benzumab injection show a unique situation. However, as time goes by, it is expected that there will be many heavy new imported drugs and domestic anti-cancer drugs listed in the next three years, and the proportion of biological agents will continue to increase. It is very likely that the Roche family will go. No return.

Five major imported anti-cancer drugs to be launched in 2018

　　 1. Two major PD-1 monoclonal antibodies are about to land in China: Nivolumab And Pembrolizumab

Nivolumab is the world's first marketed PD-1 monoclonal antibody, first approved in Japan. Since it was first approved for melanoma indications in the United States on December 22, 2014, it has been approved by the FDA for nine major indications. The application for the listing of Navumab in China's second-line treatment of NSCLC was accepted by CDE on November 2, 2017, and was included on December 18, 2017 by CDE for "there is a significant therapeutic advantage compared to existing treatments." Priority review, the drug has entered the review queuing sequence, it is expected that Q2 will be approved for listing in 2018, and it is likely to become the first PD-1/PD-L1 mAb approved in China. Nawumab's global sales in 2015 was US$982 million, and its sales in 2017 were US$49.48. It is expected that the peak sales will reach US$9.59 billion in the next five years, and it will certainly have a place in the huge anti-cancer market in China.

Nivolumab latest review status

Source: Minenet MED China Drug Review Database 2.0

Pembrolizumab, developed by Merck, was approved by the FDA on October 28, 2014 and is the first PD-1 inhibitor to be marketed in the United States. Compared with Nivolumab, pemimab is leading the first line of treatment of PD-1 in NSCLC. In 2015, Pemmumab achieved sales of US$566 million and sales in 2017 of US$3.809 billion. It is expected to reach US$9.88 billion in the next five years. Pammonab submitted its application for listing in China in February 2018. It is expected to be approved for listing in 2018Q3 and is likely to become the second PD-1/PD-L1 mAb listed in China. The strength of Pembab is due to the fact that it has established a large lead in the field of lung cancer, and on the other hand because Keytruda was approved by the FDA in May 2017 for the treatment of highly microsatellite instability (MSI-H). Or solid tumor patients with mismatch repair defects (dMMR) are the first anti-tumor therapy approved by the US FDA that does not follow the source of the tumor, but is differentiated according to biomarkers, and has a milestone significance. However, Merck lost to the BMS in the patent lawsuit. Although Keytruda grew strongly, it had to split into BMS, and the killing of two super blockbusters would continue.

　　 2. Three major imported targeted drugs: upgrading and benefiting the Chinese people

Developed by AstraZeneca, Lynparza is the world's first marketed PARP inhibitor, first approved by the FDA in December 2014 for four-line treatment of advanced BRCA+ovarian cancer, which has been approved so far. A cancer indication. To date, Lynparza has treated more than 30,000 patients with advanced cancer, and the efficacy has been fully affirmed. In 2017, the drug's global sales amounted to US$297 million, and the peak sales in the next five years are expected to reach US$1.3 billion. The Chinese listing application for Olapali's second-line treatment of ovarian cancer was accepted by CDE on December 1, 2017, and was included in the priority review. It is expected to be approved in 2018Q3, which is worth looking forward to.

Olapali in the MED China Drug Evaluation Database 2.0 search results

Developed by Eisai, Luvutinib is an oral multi-targeted kinase inhibitor that inhibits VEGFR-1, 2, 3, FGFR-1, 2, 3, 4, PDGFR, RET and KIT. Luvutinib was approved for marketing in the United States on February 13, 2015. It has been approved for the treatment of advanced thyroid and renal cancer, as well as clinical trials for indications such as hepatocellular carcinoma, glioma and non-small cell lung cancer. In progress. Luvutinib submitted a listing application to CFDA on November 3, 2017, and received a priority review. It is expected that 2018Q4 will be approved for listing in China. China is a large country with liver cancer patients. There are about 395,000 newly diagnosed liver cancer patients and 380,000 patients with liver cancer death each year. Currently, sorafenib is the first systemic treatment with clear evidence to improve the survival of patients with advanced liver cancer. The first-line clinical standard for patients with hepatocellular carcinoma in China. In a head-to-head comparison experiment with sorafenib, lunfutinib wins with a slight advantage, and good results will inevitably lead to better sales.

Search results of lunfutinib in MED China Drug Evaluation Database 2.0

Cerritinib was developed by Novartis and approved by the FDA on April 29, 2014 for crizotinib in the treatment of intolerance or disease progression in ALK+ non-small cell lung cancer, belonging to second-generation anaplastic lymphoma kinase (ALK) inhibition. Agent. Novartis's application for the marketing of sirinib capsule was officially accepted by CDE on December 11, 2017 and has been included in the priority review. It is expected to be approved by CFDA in 2018Q4. The results of the ASCEND-4 study show that sirinib has a significant advantage over standard first-line chemotherapy (pemetrexed, platinum) and is believed to have achieved good results in the Chinese anticancer market.

Search Results of Seritinib in MED China Drug Evaluation Database 2.0

Conclusion

With the drastic reform of the drug trial system in 2015, a number of policies have been implemented, and the time to market for innovative drugs and clinically urgent drugs in China has been reduced from an average of 7 to 8 years before the reform to 2 to 3 years. After a series of combination punches, it is obvious that the "blowout" period of heavy new drugs and generic drugs will be ushered in in the next few years. The strength of the domestic team is growing, the introduction of high-quality imported new drugs and the reform of the medical insurance system, the competition between anti-cancer drugs will become more and more fierce, and the price of imported anti-cancer drugs will also increase in competitive pressure and pursue greater sales. The double cause is gradually reduced. Cheap and high quality, will no longer exist only in the heart of cancer patients.

Zoom Bullet Camera

The Zoom Bullet Camera means that the Zoom Bullet Camera/ Zoom Bullet Network Camera/ Waterproof Zoom Bullet Cameras/ Zoom Bullet Camera CCTV/ Zoom Bullet Surveillance Cameras/Infrared Bullet Zoom Cameras belongs to not only the Zoom Camera but also the Bullet camera. We have introduced the basic features of the Bullet Camera before, so this time let me introduce the maintenance skills of the Bullet Camera(including th Zoom Bullet Camera)for you.

The maintenance skills of the Zoom Bullet Camera

1. The basic conditions to maintain the Zoom Bullet Camera
The basic maintenance conditions required for the normal equipment maintenance of the Zoom Bullet Camera
system are the "four complete". That is, the complete spare parts, complete accessories, complete tools, and
complete instruments.

1) Complete spare parts
Generally speaking, the corresponding spare parts library(which mainly stores some important equipment that is not easy to repair immediately after damage, such as the Bullet Cameras , lenses, monitors, etc.) must be established for the the maintenance of each system. Once these equipment fails, the system may not operate normally and must be replaced in time. Therefore, a certain number of spare parts must be available, and the inventory of the spare parts library must be continuously updated according to the repairability of the equipment and the characteristics of the operating cycle of the equipment.

2) Complete accessories
Accessories are mainly the additional configuration of the various discrete components and modules in the equipment, which are mainly used for equipment maintenance and to prepare more accessories would be better. The commonly used accessories mainly include various integrated circuit chips and circuit discrete components, required by the circuit. Other larger equipment must be equipped with the certain functional modules for the emergency use. In this way, a lot of expenses for updating equipment can be saved with a small investment.

3) complete tools and testing instruments
The Zoom Bullet Camera must be equipped with the common maintenance tools and inspection equipment, such as various pliers, screwdrivers, electric test pens, electric soldering irons, adhesive tape, multimeters, oscilloscopes, etc. If necessary, the user should also make some testing tool such as the simulated load.

2. The specific maintenance skills of the Zoom Bullet Camera

1) Dust and clean the equipment once a quarter to ensure the normal operation of the machine. Meanwhile, check the ventilation, heat dissipation, dust removal, power supply and other facilities of the monitoring room. The outdoor temperature should be -20℃~+60℃, the relative humidity should be 10%~100%; the indoor temperature should be controlled at +5℃~+35℃, and the relative humidity should be controlled at 10%~80%, make the monitoring equipment in a good operating environment.

2) According to the instructions of each part of the Zoom Bullet Camera system, check the technical parameters and the quality of the transmission line of the monitoring system every month, handle the hidden troubles, and assist the monitoring supervisor to set the various data, to ensure the good condition and normal operation of this equipment' each part' functions.

3) Thoroughly inspect the parts of the Zoom Bullet Camera equipment that are prone to aging once a month. Once the aging phenomenon is found, it should be replaced and repaired in time, such as the video head.

4) Maintain the monitoring equipment that works for a long time regularly once a month.

5) Monitor the operation of the Zoom Bullet Camera system and equipment, analyze the operation, find and

troubleshoot in time.

6) Optimize the Zoom Bullet Camera system and equipment regularly every month.

7) Provide the monthly regular information service: for example, on the first working day of each month, last month's repair and maintenance records should be submitted to the person in charge of the monitoring center, in the form of electronic files.

Zoom Bullet Network Camera, Waterproof Zoom Bullet Cameras, Zoom Bullet Camera CCTV, Zoom Bullet Surveillance Cameras, Infrared Bullet Zoom Cameras

SHENZHEN SANAN TECHNOLOGY CO.,LTD , https://www.sanan-cctv.com